Bedford Group Transearch Life Sciences Congratulates BioScript Solutions on the appointments of four key hires

by

Subscribe to receive industry-focused thought leadership and insights, delivered right to your inbox Subscribe

Bedford Group Transearch Life Sciences Congratulates BioScript Solutions on the appointments of:

Laura Smith, Director, Clinic Operations

Neil Sarin, Director, Patient Support Services

Virginie Leduc, Director, Patient Support Services

Anne-Marie Lebel, Director, Business Development

Each of these leaders brings an accomplished background from the pharmaceutical and/or pharmacy industries as BioScript continues to advance their growth agenda while continuing to put their patients first in everything they do.

About BioScript Solutions

Since 2001, BioScript Solutions has supported patients with chronic illnesses and rare diseases by providing access to complex drug therapies and delivering full-service specialty care. The company serves thousands of Canadians coast to coast every year — from our patient support programs, wholesale pharmaceutical distribution and third-party logistics to our clinics and pharmacies. Even as the company grows, BioScript remains local at heart — committed to their communities and to putting patients first in everything they do.

Please visit bioscript.ca to learn more about their specialty services.

Darren Raycroft

Darren Raycroft

Partner and Managing Director

Email: draycroft@bedfordgroup.com
Tel: 416-963-9000 x. 234

Howard Pezim

Howard Pezim

Co-Founder and Managing Director

Email: howardp@bedfordgroup.com
Tel: 416-963-9000, ext.223

Recently completed Life Sciences and Healthcare Searches

Apotex USA hires new Head of Information Technology

Apotex USA hires new Head of Information Technology

Bedford Group Trasearch Life Sciences would like to congratulate Roberto Pujol on his appointment to Head of IT with Apotex USA. Pujol was most recently the Senior Director, Information Technology with Smith & Nephew, where he directed the IT strategy for a $2B+...